Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 30, 2025 08:00 ET | Source: Celularity Inc.

Celularity and DefEYE, Inc. Partner to Advance Growth of Regenerative Therapies in Eye Care

Celularity has entered into a strategic partnership with DefEYE, granting DefEYE an exclusive sublicense for Celularity’s ophthalmic biologics portfolio
October 14, 2025 08:45 ET | Source: Celularity Inc.

Celularity Announces Peer-Reviewed Publication of Phase 2 Clinical Trial Results Demonstrating the Safety and Efficacy of Human Placenta-Derived Cells (PDA-002) for Diabetic Foot Ulcers Complicated by Peripheral Artery Disease

First-in-class regenerative therapy for diabetic foot ulcers complicated by peripheral artery diseaseCelularity PDA-002 achieved durable wound healing with just two intramuscular dosesAs a qualified...
June 02, 2025 08:00 ET | Source: Celularity Inc.

Celularity Announces Publication Advancing Ocular Surface Reconstruction with Tri-Layer Amniotic Membrane Technology

Highlights the unique potential of Celularity’s proprietary advanced biomaterial technology as a novel cellular delivery system for ocular surface reconstructionSupports broad range of regenerative...
May 30, 2025 17:30 ET | Source: Celularity Inc.

Celularity Receives Nasdaq Notice Regarding Form 10-Q

FLORHAM PARK, N.J., May 30, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity” or the “Company”), a cellular and regenerative medicine company, today announced that on May 28,...
May 09, 2025 09:15 ET | Source: Celularity Inc.

Celularity Announces Full Year 2024 Operating and Financial Results

FLORHAM PARK, N.J., May 09, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity” or the “Company”), a regenerative and cellular medicine company, today announced operating and...
April 25, 2025 17:30 ET | Source: Celularity Inc.

Celularity Receives Nasdaq Notice Regarding Non-Payment of Nasdaq Fees

FLORHAM PARK, N.J., April 25, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity” or the “Company”), a cellular and regenerative medicine company, today announced that Nasdaq has...
April 14, 2025 08:00 ET | Source: Celularity Inc.

Celularity Welcomes CMS Action on Medicare Local Coverage Determination for Skin Substitutes Products

FLORHAM PARK, N.J., April 14, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity” or the “Company”), a regenerative and cellular medicine company, welcomes action by the Centers...
April 07, 2025 08:00 ET | Source: Celularity Inc.

Celularity Announces Publication of “Senescence, NK cells, and cancer: navigating the crossroads of aging and disease” in the April 4, 2025, Issue of Frontiers in Immunology

FLORHAM PARK, N.J., April 07, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity” or the “Company”), a regenerative and cellular medicine company, today announced a key publication...
February 25, 2025 08:00 ET | Source: Celularity Inc.

Celularity Receives FDA Tissue Reference Group Recommendation Letters for its Natalin and Acelagraft™ Wound Care Products

FLORHAM PARK, N.J., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity” or the “Company”), a regenerative and cellular medicine company, today announced that on December...
February 24, 2025 08:00 ET | Source: Celularity Inc.

Celularity Enters Strategic Collaboration Agreement with Clinical Stage Cell Therapy Company

FLORHAM PARK, N.J., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity” or the “Company”), a cellular and regenerative medicine company, today announced that it has...